/ Print /

Erin Bastick, PharmD, RPh
Oral specialty drug options on the horizon
As more specialty drugs are approved, cost control strategies are key.
Brace for a barrage of biosimilars
The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Popular insulin meets target in real-world study
Novo Nordisk’s DEVOTE study reveals interesting findings.
New universal companion diagnostic paves the way for precision oncology
FDA approves new diagnostic test for non-small cell lung cancer.
New antibiotic approved for acute bacterial skin infections
FDA approved the use of a new fluoroquinolone antibiotic to treat ABSSSI.
FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosis
FDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patients
Cost burden prompts payers to consider appropriate utilization
FDA to drug maker: Pull opioid pain drug
Potential public health consquences prompts FDA to request removal of opioid pain medication.
FDA approves EpiPen rival
Adamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
FDA approves first generic Truvada for HIV
The first generic Truvada for treating and preventing HIV will be available, but when?